Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data PRECIGEN, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
191
231
151
90.7
32
14.3
26.9
6.23
3.93
9.68
Cost of revenue
37.7
33.3
Gross profit
153
198
Research and development
112
143
405
48.6
53.1
41.3
Selling, general and administrative
142
146
138
40.4
41.3
70.1
Operating expenses
316
369
666
106
139
120
Operating income
-125
-138
-506
-99.8
-135
-111
Interest expense
0.86
0.61
8.53
0.47
0.01
3.87
Other non-operating income
-47.9
22.5
-19
3.4
7
-140
Pre-tax income
-194
-78.4
-396
-171
-105
-111
-80
-96.4
-128
-251
Income tax
-3.88
2.07
-15.4
-0.93
-0.08
-0.16
-0.19
-0.46
-1.79
0
Income from continuing operations
-70.6
-375
-169
-104
-96.8
-79.8
Net income to minority interests
-3.66
-9.8
-5.37
-1.59
0
0
Net income
-187
-117
-509
-322
-171
-92.2
28.3
-95.9
-126
-251
EBITDA
-101
-107
-472
-93.1
-131
-107
EPS, basic
-1.58
-0.98
-3.93
-2.09
-1.02
-0.47
0.14
-0.39
-0.47
-1.37
EPS, diluted
-1.58
-0.98
-3.93
-2.09
-1.02
-0.47
0.14
-0.39
-0.47
-1.37
Shares, basic (weighted)
118
120
130
154
167
198
200
245
268
313
Shares, diluted (weighted)
118
120
130
154
167
198
200
245
268
313
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
62.6
68.1
96.9
65.8
51.8
36.4
4.86
7.58
29.5
30.2
Short-term investments
175
6.27
120
9.26
48.3
72.2
51.1
55.3
68.4
67.6
Receivables
21.6
19.8
21.2
20.7
16.5
1.34
0.98
0.9
0.93
3.92
Other current assets
7.36
7.06
5.33
5.83
7.19
5.47
5.07
4.33
3.34
3.43
Total current assets
315
154
285
235
149
157
118
68.8
102
115
Property, plant and equipment
64.7
113
86.9
44
34.9
8.6
7.33
7.11
13.8
13.8
Lease right-of-use assets
0
11.8
9.35
9.99
8.09
7.1
5.06
4.68
Goodwill
157
93.8
93.6
54.1
54.4
37.6
36.9
26.6
19.1
15.2
Intangible assets
226
233
89
68.3
65.4
52.3
44.5
40.7
4.46
3.18
Long-term investments
0
48.6
0
0
2.51
Other non-current assets
3.71
4.05
2.07
1.35
1.6
0.94
1.03
0.77
0.37
0.91
Total assets
949
847
716
456
315
360
216
151
145
156
Accounts payable
8.48
8.7
12
5.53
4.6
3.11
4.07
1.73
3.53
12
Accrued liabilities
6.54
6.47
9.96
13.2
8.1
7.86
6.38
8.25
8.42
10.2
Deferred revenue
53.4
42.9
11.1
5.7
2.8
1.49
0.03
0.51
0.59
0.52
Short-term debt
0.39
0.5
0.48
31.7
0.36
0.05
43.2
0
Total current liabilities
94.6
80.2
61.6
123
42.1
34.6
78.6
23
21.5
37.3
Long-term debt
7.56
7.54
211
186
172
180
0
0
93.2
Lease liabilities
0
10.1
7.74
8.75
6.99
5.9
4.55
3.98
Other non-current liabilities
3.87
3.45
3.14
0
0.1
0.05
0
0.13
Total liabilities
380
300
337
384
247
253
89.7
32.5
78.5
135
Total debt
7.95
8.04
212
218
172
180
43.2
0
93.2
Paid-in capital
1,326
1,397
1,722
1,752
1,887
2,023
1,998
2,085
2,129
2,362
Retained earnings
-729
-848
-1,331
-1,653
-1,823
-1,916
-1,869
-1,964
-2,091
-2,341
Other comprehensive income
-36.2
-15.6
-28.6
-27.5
4
0.2
-3.49
-1.95
0.01
0.01
Shareholders' equity
560
534
363
71.7
67.2
107
126
118
38.5
20.9
Minority interests
9.01
12.9
15.9
0
Total equity
569
547
379
71.7
67.2
107
126
118
38.5
20.9
Total liabilities and equity
949
847
716
456
315
360
216
151
145
156
Shares outstanding
119
122
160
163
188
207
208
249
293
354
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-190
-127
-515
-324
-171
-92.2
28.3
-95.9
-126
-251
Depreciation and amortization
24.6
31.1
33.1
24.9
17.5
13.8
10.8
6.67
4.53
3.2
Stock-based compensation
42.2
41.6
36.3
19
18.4
13.9
10.2
9.89
9.47
10.9
Deferred income tax
-3.47
-2.53
-21.3
-3.67
-0.16
-0.17
-0.15
-0.48
-1.8
0
Change in receivables
2.59
0.74
-2.7
-0.26
2.21
-6.23
-2.18
0.08
-0.02
-2.99
Change in inventory
3.81
0.66
-0.48
4.1
2.51
-1.9
2.34
0
0
-9.21
Change in payables
3.62
-3.4
4.68
Cash from operations
-49
-104
-124
-136
-77
-55.8
-65
-66.9
-68.2
-87.8
Capital expenditures
-31.6
-46.7
-41.6
-37.9
-7.53
-7.25
-4.92
-1.54
-8.58
-2
Acquisitions
0
2.05
-0.92
0
0
Purchases of investments
-75.2
0
-179
-55.1
-171
-174
0
-185
-187
-208
Sales and maturities of investments
102
175
66
Cash from investing
-28.4
104
-151
86.9
27.8
-74.5
226
-3.09
-20.7
-1.54
Debt issued
0.55
0.33
220
0.38
0
0
0
0
92.8
Debt repaid
-1.2
-0.52
-0.62
-0.62
-0.49
-0.47
-155
-43.2
0
0
Stock issued
0
0
0
72.8
31.2
-0.36
Cash from financing
12.1
4.28
310
8.14
32.7
121
-155
29.6
111
90
Exchange rate effect
-0.87
1.06
0.3
-0.81
0.35
0.22
-0.83
-0.32
-0.03
0.04
Net change in cash
-66.2
5.95
34.6
-41.7
-16.2
-8.91
5.25
-40.7
21.7
0.72
Free cash flow
-80.6
-150
-166
-174
-84.5
-63
-70
-68.5
-76.8
-89.8
Interest paid
0.96
0.62
3.87
3.75
7.2
7.16
8.54
1.17
0.01
3.51
Income taxes paid
0.01
0.57
0.22
0.05
0.05
0.04
0
0.02
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $7.75 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-361.9%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-92.6%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
146.7%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-28.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-21.3%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-45.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-45.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-20.8%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
7.0%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-10.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-13.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
16.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
16.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
13.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.58x
Current assets / current liabilities.
Quick ratio
3.75x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.30x
(Cash + short-term investments) / current liabilities.
Debt / equity
2.15x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
55.1%
Total debt / total assets.
Liabilities / assets
74.4%
Total liabilities / total assets.
Net debt
$55.7M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.28
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.28
Cash from operations / diluted weighted shares.
Book value per share
$0.12
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
63.7x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
108x
Market cap / tangible book value, when positive.
FCF yield
-4.2%
Free cash flow / market cap.
Earnings yield
-5.7%
Net income / market cap (the inverse of P/E).
What was PRECIGEN, INC.'s revenue in fiscal 2025?
PRECIGEN, INC. reported revenue of $9.7M for fiscal 2025, 146.7% higher than the year before.
Was PRECIGEN, INC. profitable in fiscal 2025?
No. It reported a net loss of $250.6M.
How much free cash flow did PRECIGEN, INC. generate in fiscal 2025?
Cash from operations of $87.8M minus capital expenditures of $2.0M left free cash flow of -$89.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.